Molecular chemotherapy

A. Deisseroth, Takuma Fujii, X. Peng, L. Zhang, D. Austin, T. Rutherford, J. Brandsma, P. E. Schwartz

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

For the past 50 years, during which chemotherapy has been administered for the treatment of cancer, the paradigm driving the selection of chemotherapeutic agents was their capability to damage the DNA of dividing cells. In addition, chemotherapeutic agents were studied for the selectivity of their toxic effect to the cancer cell versus the normal cell. Because many of the normal cells in the body shared the phenotype of cellular division with the tumor cells, the drugs developed for the treatment of cancer displayed only relative selectivity for the cancer cell. The advent of structural biology and computational chemistry to drug development, and the explosion of information about the molecular and genetic changes acquired in the cancer cell, have now produced the opportunity to design drugs for cancer treatment which specifically block the effects of the signals within cancer cells which drive the evolution of the disease process to unregulated cell growth. The implementation of this new mode of drug design to the field of cancer chemotherapy is the subject of this chapter.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalCME Journal of Gynecologic Oncology
Volume6
Issue number1
Publication statusPublished - 01-01-2001
Externally publishedYes

Fingerprint

Drug Therapy
Neoplasms
Drug Design
Explosions
Poisons
Computational Biology
Pharmaceutical Preparations
DNA Damage
Molecular Biology
Therapeutics
Phenotype
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Deisseroth, A., Fujii, T., Peng, X., Zhang, L., Austin, D., Rutherford, T., ... Schwartz, P. E. (2001). Molecular chemotherapy. CME Journal of Gynecologic Oncology, 6(1), 23-28.
Deisseroth, A. ; Fujii, Takuma ; Peng, X. ; Zhang, L. ; Austin, D. ; Rutherford, T. ; Brandsma, J. ; Schwartz, P. E. / Molecular chemotherapy. In: CME Journal of Gynecologic Oncology. 2001 ; Vol. 6, No. 1. pp. 23-28.
@article{6cf195fcdbd942bc8f3b7d2e8c16a399,
title = "Molecular chemotherapy",
abstract = "For the past 50 years, during which chemotherapy has been administered for the treatment of cancer, the paradigm driving the selection of chemotherapeutic agents was their capability to damage the DNA of dividing cells. In addition, chemotherapeutic agents were studied for the selectivity of their toxic effect to the cancer cell versus the normal cell. Because many of the normal cells in the body shared the phenotype of cellular division with the tumor cells, the drugs developed for the treatment of cancer displayed only relative selectivity for the cancer cell. The advent of structural biology and computational chemistry to drug development, and the explosion of information about the molecular and genetic changes acquired in the cancer cell, have now produced the opportunity to design drugs for cancer treatment which specifically block the effects of the signals within cancer cells which drive the evolution of the disease process to unregulated cell growth. The implementation of this new mode of drug design to the field of cancer chemotherapy is the subject of this chapter.",
author = "A. Deisseroth and Takuma Fujii and X. Peng and L. Zhang and D. Austin and T. Rutherford and J. Brandsma and Schwartz, {P. E.}",
year = "2001",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "23--28",
journal = "CME Journal of Gynecologic Oncology",
issn = "1219-9087",
publisher = "Primed-X Press",
number = "1",

}

Deisseroth, A, Fujii, T, Peng, X, Zhang, L, Austin, D, Rutherford, T, Brandsma, J & Schwartz, PE 2001, 'Molecular chemotherapy', CME Journal of Gynecologic Oncology, vol. 6, no. 1, pp. 23-28.

Molecular chemotherapy. / Deisseroth, A.; Fujii, Takuma; Peng, X.; Zhang, L.; Austin, D.; Rutherford, T.; Brandsma, J.; Schwartz, P. E.

In: CME Journal of Gynecologic Oncology, Vol. 6, No. 1, 01.01.2001, p. 23-28.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Molecular chemotherapy

AU - Deisseroth, A.

AU - Fujii, Takuma

AU - Peng, X.

AU - Zhang, L.

AU - Austin, D.

AU - Rutherford, T.

AU - Brandsma, J.

AU - Schwartz, P. E.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - For the past 50 years, during which chemotherapy has been administered for the treatment of cancer, the paradigm driving the selection of chemotherapeutic agents was their capability to damage the DNA of dividing cells. In addition, chemotherapeutic agents were studied for the selectivity of their toxic effect to the cancer cell versus the normal cell. Because many of the normal cells in the body shared the phenotype of cellular division with the tumor cells, the drugs developed for the treatment of cancer displayed only relative selectivity for the cancer cell. The advent of structural biology and computational chemistry to drug development, and the explosion of information about the molecular and genetic changes acquired in the cancer cell, have now produced the opportunity to design drugs for cancer treatment which specifically block the effects of the signals within cancer cells which drive the evolution of the disease process to unregulated cell growth. The implementation of this new mode of drug design to the field of cancer chemotherapy is the subject of this chapter.

AB - For the past 50 years, during which chemotherapy has been administered for the treatment of cancer, the paradigm driving the selection of chemotherapeutic agents was their capability to damage the DNA of dividing cells. In addition, chemotherapeutic agents were studied for the selectivity of their toxic effect to the cancer cell versus the normal cell. Because many of the normal cells in the body shared the phenotype of cellular division with the tumor cells, the drugs developed for the treatment of cancer displayed only relative selectivity for the cancer cell. The advent of structural biology and computational chemistry to drug development, and the explosion of information about the molecular and genetic changes acquired in the cancer cell, have now produced the opportunity to design drugs for cancer treatment which specifically block the effects of the signals within cancer cells which drive the evolution of the disease process to unregulated cell growth. The implementation of this new mode of drug design to the field of cancer chemotherapy is the subject of this chapter.

UR - http://www.scopus.com/inward/record.url?scp=0034907932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034907932&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0034907932

VL - 6

SP - 23

EP - 28

JO - CME Journal of Gynecologic Oncology

JF - CME Journal of Gynecologic Oncology

SN - 1219-9087

IS - 1

ER -

Deisseroth A, Fujii T, Peng X, Zhang L, Austin D, Rutherford T et al. Molecular chemotherapy. CME Journal of Gynecologic Oncology. 2001 Jan 1;6(1):23-28.